Denali Therapeutics Net Income Over Time
| DNLI Stock | USD 19.18 0.51 2.59% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Denali Therapeutics Performance and Denali Therapeutics Correlation. Is there potential for Biotechnology market expansion? Will Denali introduce new products? Factors like these will boost the valuation of Denali Therapeutics. Projected growth potential of Denali fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Denali Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Denali Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Denali Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Denali Therapeutics and related stocks such as Arcus Biosciences, Agios Pharm, and 89bio Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RCUS | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (53.1 M) | (49.6 M) | (75.9 M) | (123 M) | 53 M | (267 M) | (307 M) | (283 M) | (254.7 M) | (242 M) |
| AGIO | (23.7 M) | (23.7 M) | (20.1 M) | (39.4 M) | (53.5 M) | (117.7 M) | (198.5 M) | (314.7 M) | (346 M) | (411.5 M) | (327.4 M) | 1.6 B | (231.8 M) | (352.1 M) | 673.7 M | 774.8 M | 813.5 M |
| IBRX | (2 M) | (2 M) | (2 M) | (2 M) | (6.2 M) | (236.9 M) | (120.8 M) | (96.4 M) | (96.2 M) | (65.8 M) | (221.9 M) | (346.8 M) | (416.6 M) | (583.2 M) | (413.6 M) | (372.2 M) | (353.6 M) |
| BEAM | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (115.3 M) | (78.3 M) | (194.6 M) | (370.6 M) | (289.1 M) | (132.5 M) | (376.7 M) | (339.1 M) | (322.1 M) |
| RXRX | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (62.5 M) | (87 M) | (178.1 M) | (239.4 M) | (328.1 M) | (463.7 M) | (417.3 M) | (396.4 M) |
| COGT | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (18.1 M) | (25.5 M) | (34.5 M) | (30.3 M) | (74.8 M) | (72.3 M) | (132.6 M) | (192.4 M) | (255.9 M) | (230.3 M) | (218.8 M) |
| GLPG | (3.6 M) | (33.1 M) | (5.7 M) | (8.1 M) | 33.2 M | (118.4 M) | 54 M | (115.7 M) | (29.3 M) | 149.8 M | (305.4 M) | (125.4 M) | (218 M) | 211.7 M | 74.1 M | 66.7 M | 70 M |
| LQDA | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (29.2 M) | (53.1 M) | (47.6 M) | (59.8 M) | (34.6 M) | (41 M) | (78.5 M) | (130.4 M) | (117.4 M) | (111.5 M) |
| VRDN | (7.2 M) | (7.2 M) | (7.2 M) | (2.2 M) | (7.9 M) | (11.3 M) | (12.7 M) | (26.5 M) | (32.7 M) | (41.9 M) | (110.7 M) | (79.4 M) | (129.9 M) | (237.7 M) | (269.9 M) | (243 M) | (230.8 M) |
Denali Therapeutics and related stocks such as Arcus Biosciences, Agios Pharm, and 89bio Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Denali Therapeutics financial statement analysis. It represents the amount of money remaining after all of Denali Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Denali Therapeutics | DNLI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 161 Oyster Point |
| Exchange | NASDAQ Exchange |
USD 19.18
Check out Denali Therapeutics Performance and Denali Therapeutics Correlation. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Denali Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.